Q1 2023 Results

Company overview Financial review Conclusions Appendix References Strong top and bottom line growth in Q1 Group1 Q1 Change vs. PY USD million 2023 % USD % CC Net Sales 12,953 3 8 Core Operating income 4,413 8 15 Operating income 2,856 0 9 Net income 2,294 3 14 Core EPS (USD) 1.71 17 25 25 EPS (USD) 1.09 9 20 20 Free Cash Flow 2,720 95 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 35 of the Condensed Interim Financial Report. 22 Investor Relations | Q1 2023 Results FINANCIAL PROFILE ✓ NOVARTIS | Reimagining Medicine

View entire presentation